Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis.

Autor: Gupta AK; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Mediprobe Research Inc., London, Ontario, Canada., Venkataraman M; Mediprobe Research Inc., London, Ontario, Canada., Shear NH; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Department of Medicine (Dermatology, Clinical Pharmacology and Toxicology), Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; Department of Pharmacology, Sunnybrook and Women's College Health Science Centre, Toronto, Ontario, Canada., Piguet V; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada.
Jazyk: angličtina
Zdroj: Dermatologic therapy [Dermatol Ther] 2020 Jul; Vol. 33 (4), pp. e13613. Date of Electronic Publication: 2020 Jul 18.
DOI: 10.1111/dth.13613
Abstrakt: Onychomycosis is a difficult to treat condition whose prevalence is increasing. Until recently, there was no FDA approved antifungal agent for the treatment of onychomycosis in children. Although systemic antifungal agents are effective, their use is restricted by the potential adverse events and drug-drug interactions. There is evidence regarding the safety and efficacy of topical antifungal agents for pediatric onychomycosis. We have summarized the results of a recently published study using efinaconazole topical solution 10% to treat onychomycosis in children and discuss management of pediatric onychomycosis. In a multicenter, open-label phase 4 study, efinaconazole 10% solution was applied topically once daily in children aged 6 to 16 years with mild to severe, culture positive, distal and lateral subungual onychomycosis. Treatment was for 48 weeks with a follow-up at week 52. Pharmacokinetics was performed in a subset of patients. There were 62 patients enrolled in the study. At week 52, the efficacy was mycological cure rate 65% and complete cure rate 40%. All treatment-emergent adverse events (TEAE) were mild to moderate in severity with none resulting in study discontinuation. The only treatment-related TEAE was ingrown toenail. Efinaconazole was detected at low levels in plasma. Efinaconazole topical solution 10% is effective and safe in treating onychomycosis in children age 6 to 16 years and was recently FDA-approved for this indication. The on-label use of other topical agents, tavaborole solution 5% and ciclopirox nail lacquer solution 8% is reviewed. We also briefly discuss the use of oral agents, terbinafine, itraconazole, and fluconazole in pediatric onychomycosis.
(© 2020 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje